FDA Approval Insights: Nivolumab/Cabozantinib in Advanced RCC

Season 4 Episode 25  ·  Jan 25, 2021, 09:04 PM

Headliner
Share
Subscribe

In our exclusive interview, Toni K. Choueiri, MD, provides additional perspective on the FDA approval of nivolumab and cabozantinib in advanced RCC.

Share
Subscribe
Next
Markman Talks Vilified Vaccines, Taboos, and Treatment for Cervical Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air